-
Mashup Score: 7
Circulating-tumor DNA (ctDNA)-positive status was a negative prognostic biomarker in patients with muscle-invasive urothelial carcinoma after radical surgery and possibly a predictive biomarker for the overall survival benefit with adjuvant atezolizumab versus observation. The ctDNA-negative status possibly identified patients who experienced an unfavorable risk-benefit profile with adjuvant atezolizumab.
Source: www.europeanurology.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 68
Surgery remains the standard for lymph-node (LN) metastatic penile cancer. Surveillance or delayed LN dissection (LND) risks missing a curative opportunity. Minimally invasive techniques seem to be feasible and may reduce wound related complications. (Neo)adjuvant treatment has no proven benefit in pN1 disease. More advanced disease is rarely cured by surgery alone and multimodal treatment should be considered after multidisciplinary team discussion. Further prospective and randomised trials on minimally invasive LND, multimodal/novel systemic therapies, and management of recurrent LN are needed.
Source: www.europeanurology.comCategories: General Medicine News, UrologyTweet-
Congrats to our March IMPACT Award winners @AshwinUrol and Luke McGuinness! Their article “Management of Lymph Node–positive Penile Cancer: A Systematic Review” was the most influential work featured in our March 2024 issue! Full article here: https://t.co/QVpLGFZ0k0 #UroSoMe https://t.co/d0dXqWn6Ie
-
-
Mashup Score: 4
It is not known whether molecular urothelial cancer (UC) subtypes change during metastatic evolution. Immunohistochemistry-based and histomorphological UC subtypes remain highly stable during metastasis. The luminal tumor cell differentiation of “stroma-rich” tumors based on immunohistochemical subtyping is apparently superimposed by desmoplastic tumor stroma content in transcriptome-based subtyping.
Source: www.europeanurology.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 48Management of Lymph Node–positive Penile Cancer: A Systematic Review - 1 month(s) ago
Surgery remains the standard for lymph-node (LN) metastatic penile cancer. Surveillance or delayed LN dissection (LND) risks missing a curative opportunity. Minimally invasive techniques seem to be feasible and may reduce wound related complications. (Neo)adjuvant treatment has no proven benefit in pN1 disease. More advanced disease is rarely cured by surgery alone and multimodal treatment should be considered after multidisciplinary team discussion. Further prospective and randomised trials on minimally invasive LND, multimodal/novel systemic therapies, and management of recurrent LN are needed.
Source: www.europeanurology.comCategories: General Medicine News, UrologyTweet-
Congrats to our March IMPACT Award winners @AshwinUrol and Luke McGuinness! Their article “Management of Lymph Node–positive Penile Cancer: A Systematic Review” was the most influential work featured in our March 2024 issue! Full article here: https://t.co/QVpLGFZ0k0 #UroSoMe https://t.co/d0dXqWn6Ie
-
-
Mashup Score: 10Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer - 1 month(s) ago
We conducted a trial in which effective multimodal therapies without long-term castration were combined with the aim of achieving durable remission in patients with de novo oligometastatic prostate cancer. Here we report primary analysis results from SOLAR, a single-arm prospective phase 2 trial of primary tumor–directed therapy, metastasis-directed therapy (MDT) [1], and intensified systemic therapy of limited duration conducted within the Veterans Affairs health care system.
Source: www.europeanurology.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11Germline Exome Sequencing for Men with Testicular Germ Cell Tumor Reveals Coding Defects in Chromosomal Segregation and Protein-targeting Genes - 1 month(s) ago
This exome sequencing study of 293 men with familial or bilateral testicular germ cell tumor (TGCT) and 3157 cancer-free controls is the largest of its kind. Using a gene-agnostic approach, we identified germline coding changes associated with TGCT.
Source: www.europeanurology.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 14Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial - 1 month(s) ago
In men with prostate-specific membrane antigen–defined, oligorecurrent M1a–b prostate cancer, short-course androgen annihilation therapy and metastasis-directed stereotactic body radiotherapy achieved a substantial disease-free interval following testosterone recovery. This regimen was well tolerated, and 90% of patients completed therapy with androgen deprivation therapy and at least one androgen receptor pathway inhibitor.
Source: www.europeanurology.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 26Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer - 1 month(s) ago
Circulating tumour DNA (ctDNA) has clinical applications as a “liquid biopsy” owing to its short half-life, noninvasive collection modalities, and propensity for sampling across populations of tumour cells [1]. While successful ctDNA detection has been demonstrated in metastatic prostate cancer [2], localised disease yields low levels of ctDNA, making detection difficult using conventional methods [3].
Source: www.europeanurology.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 9Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605 - 2 month(s) ago
Systemic atezolizumab demonstrated modest efficacy in patients with bacillus Calmette-Guérin–unresponsive high-risk non–muscle-invasive bladder cancer who were ineligible for or declined radical cystectomy. However, this benefit must be balanced carefully with the risk of disease progression and treatment-related toxicity.
Source: www.europeanurology.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 25Redefining Rare Genitourinary Cancers: An Initiative Led by the Global Society of Rare Genitourinary Tumors - 2 month(s) ago
Rare cancers account for 20–25% of all cancers diagnosed annually but there is no consensus on the definition of a rare cancer and substantial geographic heterogeneity. The Global Society of Rare Genitourinary Tumors is dedicated to education and research for rare genitourinary tumors.
Source: www.europeanurology.comCategories: General Medicine News, UrologyTweet
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma - European Urology https://t.co/rkxume8mva